Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment
Open Access
- 14 November 2023
- journal article
- review article
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 20 (3) , 251-258
Abstract
One of the causes of non-tumor related hyperprolactinemia is taking a medications. Physicians of various specialties, such as cardiologists, gastroenterologists, endocrinologists, and neurologists, encounter hyperprolactinemia as a side effect of drug therapy in their practice, but it is most often observed in the practice of a psychiatrist when treating patients with psychotropic medications. Over the past few years, there has been an increase in the frequency of prescriptions of antidepressants and neuroleptics due to post-COVID-19 syndrome, anxiety and stress caused by the pandemic of a new coronavirus infection. There is also a predisposition to the development of hyperprolactinemia on the background of taking neuroleptics due to genetic features of patients. Currently, there is no established common algorithm for diagnosis and treatment of drug-induced hyperprolactinemia in the world. Based on a review of foreign and domestic literature, the article discusses in detail the mechanisms of development and various approaches to the correction of iatrogenic (drug-induced) hyperprolactinemia, assesses the prolactogenic activity of neuroleptics, and proposes algorithms for prolactin monitoring and correction of hyperprolactinemia using dopamine agonists. Often the tactics of management of such patients need to be discussed by a team of specialized physicians.Keywords
This publication has 40 references indexed in Scilit:
- Hyperprolactinemia associated with psychotropics—a reviewHuman Psychopharmacology: Clinical and Experimental, 2010
- Antipsychotics and hyperprolactinaemia: mechanisms, consequences and managementClinical Endocrinology, 2010
- Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophreniaJournal of Psychopharmacology, 2009
- Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophreniaJournal of Psychopharmacology, 2008
- Medication-Induced HyperprolactinemiaMayo Clinic Proceedings, 2005
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- Elevation of Prolactin Levels by Atypical AntipsychoticsAmerican Journal of Psychiatry, 2002
- Prevalence of Abuse and Dependency in Chronic Pain PatientsInternational Journal of the Addictions, 1995
- Effects of Calcium Channel Blockade withVerapamil on the Prolactin Responsesto TRH, L-Dopa, and BromocriptineThe American Journal of the Medical Sciences, 1992
- Pharmacologic Causes of HyperprolactinemiaSeminars in Reproductive Medicine, 1984